Peritransplant tolerance induction with anti-CD3 immunotoxin: A matter of proinflammatory cytokine control

Transplantation

Volumn 65, Issue 9, 1998, Pages 1159-1169

  Contreras, Juan L ^a   Wang, Pei X ^a   Eckhoff, Devin E ^a   Lobashevsky, Andrew L ^a   Asiedu, Clement ^a   Frenette, Luc ^b   Robbin, Michelle L ^c   Hubbard, William J ^a   Cartner, Samuel ^a   Nadler, Steven ^d   Cook, William J ^b   Sharff, Joshua ^e   Shiloach, Joseph ^f   Thomas, Francis T ^a   Neville Jr , David M ^e   Thomas, Judith M ^a,b  

^a UAB Department of Surgery   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; IMMUNOTOXIN; INTERLEUKIN 12; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; INTERFERON PRODUCTION; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CYTOKINES; GRAFT SURVIVAL; GUANIDINES; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; INFLAMMATION MEDIATORS; INTERFERON TYPE II; INTERLEUKIN-12; KIDNEY TRANSPLANTATION; MACACA MULATTA; MALE; NF-KAPPA B; PHYTOHEMAGGLUTININS;

EID: 0032525243     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199805150-00003     Document Type: Article

References (66)

1. Monaco AP, Wood ML, Maki T. Induction of immunological tolerance to allografts with antilymphocyte serum and donor-specific bone marrow. In: Auchincloss H, ed. Transplantation immunology. New York: Wiley-Liss, 1995: 247.
2. Ildstad ST, Colson YL. Mixed allogeneic chimerism (A+B>A): donor-specific transplantation tolerance, superior immunocompetence, and a role for graft-facilitating cells. In: Ildstad ST, ed. Chimerism and tolerance. Austin, TX: R.G. Landes, 1995: 159.
3. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today 1988; 9(1): 23.
4. Naji A. Induction of tolerance by intrathymic inoculation of alloantigen. Current Opin Immunol 1996; 8: 704.
5. Sykes M. Chimerism and central tolerance [Review]. Current Opin Immunol 1996; 8: 694.
6. Wood KJ. Antigen induced tolerance. In: Ildstad ST, ed. Chimerism and tolerance. New York: Springer-Verlag, 1995: 15.
7. Sykes M, Szot G, Swenson K, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nature Med 1997; 3: 783.
8. Bieber CP, Jamieson S, Raney A, et al. Cardiac allograft survival in rhesus primates treated with combined total lymphoid irradiation and rabbit antithymocyte globulin. Transplantation 1979; 28(4): 347.
9. Myburgh JA, Smit JA, Hill RRH, Browde S. Transplantation tolerance in primates following total lymphoid irradiation and allogeneic bone marrow injection. II. Renal allografts. Transplantation 1980; 29: 405.
10. Pennock JL, Reitz BA, Bieber CP, et al. Survival of primates following orthotopic cardiac transplantation treated with total lymphoid irradiation and chemical immune suppression. Transplantation 1981; 32(6): 467.
11. Moses R, Orr K, Bacher J, Sachs D, Clark R, Gress R. Cardiac allograft survival across major histocompatibility complex barriers in the rhesus monkey following T lymphocyte depleted autologous marrow transplantation. Transplantation 1983; 47(3): 435.
12. Thomas J, Carver M, Cunningham P, Park K, Gonder J. Promotion of incompatible allograft acceptance in rhesus monkeys given post-transplant antithymocyte globulin and donor bone marrow. I. In vivo parameters and immunohistologic evidence suggesting microchimerism. Transplantation 1987; 43(3): 332.
13. Thomas JM, Carver M, Cunningham P, Sash C, Park K, Thomas F. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. II. Effects of adjuvant immunosuppressive drugs. Transplantation 1989; 47: 209.
14. Thomas JM, Carver FM, Cunningham PRG, Olson LC, Thomas FT. Kidney allograft tolerance in primates without chronic immunosuppression: the role of veto cells. Transplantation 1991; 51: 198.
15. Thomas J, Alqaisi M, Cunningham P, et al. The development of a posttransplant TLI treatment strategy that promotes organ allograft acceptance without chronic immunosuppression. Transplantation 1992; 53: 247.
16. Thomas JM, Carver FM, Kasten-Jolly J, et al. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation 1994; 57: 101.
17. Thomas JM, Verbanac KM, Smith JP, et al. The facilitating effect of one-DR sharing in renal allograft tolerance induced by donor bone marrow in rhesus monkeys. Transplantation 1995; 59: 245.
18. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256.
19. Thomas JM, Thomas FT. A preclinical view of transplant tolerance and chimerism: tolerance induction by posttransplant lymphoid irradiation and donor bone marrow. In: Ildstad S, ed. Chimerism and tolerance. Heidelberg: Springer-Verlag, 1995: 143.
20. Leonard A, Jonker M, Lagaaij E. Complete withdrawal of immunosuppression in allograft recipients. Transplantation 1996; 61: 1648.
21. Thomas JM, Verbanac KM. Tolerance induction: basis concepts and therapeutic approaches. In: Lieberman R, Mukherjee A, eds. Principles of drug development in transplantation and autoimmunity. Austin, TX: R.G. Landes, 1996.
22. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1.
23. Thomas JM, Neville DMJ, Contreras JL, et al. Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3 immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 1997; 64: 124.
24. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 709.
25. Neville DM Jr, Scharff J, Srinivasachar K. In vivo T-cell ablation by a holo-immunotoxin directed at human CD3. Proc Natl Acad Sci USA 1992; 89: 2585.
26. Neville DM Jr, Scharff J, Hu HZ, et al. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9. J Immunother Emphasis Tumor Immunol 1996; 19: 85.
27. Neville DMJ, Scharff J, Srinivasachar K. Anti-T cell immunotoxins: a look at post-endocytic receptor-mediated routing. J Controlled Release 1995; 24: 133.
28. Slierendregt BL, van Noort JT, Bakas RM, Otting N, Jonker M, Bontrop RE. Evolutionary stability of transspecies major histocompatibility complex class II DRB lineages in humans and rhesus monkeys. Hum Immunol 1992; 35(1): 29.
29. Slierendregt BL, Otting N, van Besouw N, Jonker M, Bontrop R. Expansion and contraction of rhesus macaque DRB regions by duplication and deletion. J Immunol 1994; 152: 2298.
30. Tepper MA, Nadler SG, Esselstyn JM, Sterbenz KG. Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. J Immunol 1995; 155: 2427.
31. Nadler SG, Eversole AC, Tepper MA, Cleaveland JS. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit 1995; 17: 700.
32. Rogge L, Barberis-Maino L, Biffi M, et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 1997; 185: 825.
33. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity [Review]. Annu Rev Immunol 1995; 13: 251.
34. Abbs IC, Clark M, Waldmann H, Chatenoud L, Koffman CG, Sacks SH. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. Ther Immunol 1994; 1: 325.
35. Chatenoud L. Use of CD3 antibodies in transplantation and autoimmune diseases [Review]. Transplant Proc 1994; 26: 3191.
36. Amemiya H. Discovery, rationale and clinical status of 15-deoxyspergualin (DSG). In: Lieberman R, Mukherjee A, eds. Principles of drug developments and toxicology of DSG. Austin, TX: R.G. Landes, 1996: 383.
37. Tepper MA. In vitro pharmacology, mechanism of action and preclinical pharmacokinetics and toxicology of DSG. In: Lieberman R, Mukherjee A, eds. Principles of drug development in transplantation and autoimmunity. Austin, TX: R.G. Landes, 1996: 383.
38. Siegall CB, Liggitt D, Chace D, Tepper MA, Fell HP. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci USA 1994; 91: 9514.
39. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
40. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 1994; 6: 157.
41. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12 [see comments]. J Natl Cancer Inst 1995; 87: 581.
42. Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 1997; 185: 817.
43. Szabo SJ, Jacobson NG, Dighe AS, Gubler U, Murphy KM. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 1995; 2: 665.
44. Nakamura T, Kamogawa Y, Bottomly K, Flavell RA. Polarization of IL-4- and IFN-gamma-producing CD4+ T cells following activation of naive CD4+ T cells. J Immunol 1997; 158: 1085.
45. Monaco AP, Wood ML, Maki T, Gozzo J. The use of donor-specific bone marrow to induce specific unresponsiveness (tolerance). In: Ildstad ST, ed. Chimerism and tolerance. New York: Springer-Verlag, 1995: 99.
46. Sykes M, Sachs DH, Strober S. Mechanisms of tolerance. In: Forman SJ, Blume KJ, Thomas ED, eds. Bone marrow transplantation. Boston: Blackwell Scientific Publications, 1994: 204.
47. Cobbold SP, Adams E, Marshall SE, Davies JD, Waldmann H. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8 [Review]. Immunol Rev 1996; 149: 5.
48. Waaga AM, Ulricks K, Krzymanski J, et al. The immunosuppressive agent 15-deoxyspergualin induces tolerance and modulates MHC-antigen expression and interleukin-1 production in the early phase of rat allograft responses. Transplant Proc 1990; 22: 1613.
49. Meng G, Jiang Y, Hubbard WJ, Thomas JM. The effect of anti-CD3-immunotoxin on T lymphocyte function in vitro. Transplant Immunol (in press).
50. Jacobson NG, Szabo SJ, Guler ML, Gorham JD, Murphy KM. Regulation of interleukin-12 signalling during T helper phenotype development [Review]. Adv Exp Med Biol 1996; 409: 61.
51. Strom TB, Roy-Chaudhury P, Manfro R, et al. The Th1/Th2 paradigm and the allograft response [Review]. Curr Opin Immunol 1996; 8: 688.
52. Hoeger PH, Tepper MA, Faith A, Higgins JA, Lamb JR, Geha RS. Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J Immunol 1994; 153: 3908.
53. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis [see comments]. Science 1995; 270: 286.
54. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system [Review]. Annu Rev Immunol 1994; 12: 141.
55. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases [Review]. N Engl J Med 1997; 336: 1066.
56. Tovey MG, Benizri E, Gugenheim J, et al. Role of the type I interferons in allograft rejection [Review]. J Leukoc Biol 1996; 59: 512.
57. Piccotti JR, Chan SY, VanBuskirk AM, Eichwald EJ, Bishop DK. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? [Overview]. Transplantation 1997; 63: 619.
58. Nickerson P, Steiger J, Zheng XX, et al. Manipulation of cytokine networks in transplantation: false hope or realistic opportunity for tolerance? [Overview]. Transplantation 1997; 63: 489.
59. Raisanen-Sokolowski A, Mottram PL, Glysing-Jensen T, Satoskar A, Russell ME. Heat transplants in interferon-y, interleukin-4, and interleukin-10 knockout mice. J Clin Invest 19977; 100: 2449.
60. Lakkis FG, Konieczny BT, Saleem S, et al. Blocking the CD28-B7 T cell costimulation pathway induces long-term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997; 158: 2443.
61. Saleem S, Konieczny BT, Lowry RP, Baddoura FK, Lakkis FG. Acute rejection of vascularized heart allografts in the absence of IFN-γ. Transplantation 1996; 62: 1908.
62. Dorling A, Lechler RI. The passenger leukocyte, dendritic cell and antigen-presenting cell (APC). In: Strom TB, Paul LC, eds. Transplant biology: cellular and molecular aspects. Philadelphia: Lippincott-Raven, 1996: 355.
63. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271.
64. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells [see comments]. Nature 1997; 388: 782.
65. Pierre P, Turley SJ, Gatti E, et al. Developmental regulation of MHC class II transport in mouse dendritic cells [see comments]. Nature 1997; 388: 787.
66. Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells [see comments]. Science 1996; 271: 1723.